ckd and semaglutide Semaglutides Are Poised to Remake Chronic Kidney Disease Care ADA 2026 - High-dose subcutaneous

SURPASS-2: The Only Head-to-Head Trial The SURPASS-2 trial (NEJM, 2021) is the most important study in this comparison because it directly tested tirzepatide against semaglutide in 1,879 patients with type 2 diabetes over 40 weeks

The exclusion criteria were: females who were pregnant or experiencing a menstrual period, type 2 diabetes treated using an insulin regimen, malignancy, hematopathy, active tuberculosis, peptic ulcer with gastric bleeding, binge-eating disorder, psychiatric disease, congestive heart failure, clinically relevant renal or hepatic insufficiency, unstable coronary artery disease, cancer or a history of cancer

Potential exceptions exist when the prescriber can show a patient has a medical need for a formulation significantly different from the commercial product, for example, an allergy to an inactive ingredient in the approved drug

Missing doses, forgetting injection sites, or losing track of your schedule can undermine your progress and leave you feeling uncertain about whether you're doing everything right

Investors may want to watch for any FDA response, potential adjustments to marketing or pricing, and how customers and partners react to the added scrutiny on Hims & Hers Health's weight management business